Page URL:

Genetic study identifies new type of muscular dystrophy

13 February 2017
Appeared in BioNews 888

Scientists have identified a unique form of congenital muscular dystrophy (MD), characterised by short stature, intellectual disabilities and cataracts.

The disorder, which shares symptoms with another muscle-weakness disorder, Marinesco-Sjögren syndrome, is caused by a mutation in the INPP5K gene, previously not associated with MD. 

'Families and physicians have been searching for the origins of this rare disorder for years,' said study co-author Dr Chiara Manzini from The George Washington University.

'Children with a similar combination of symptoms had been described in the medical literature before, but it was unclear whether or not it was a new disease. Now we know it's a variant of MD that affects other organs.'

The study, published in the American Journal of Human Genetics, initially examined the DNA of five affected children from four families. A technique called whole-exome sequencing – which specifically looks at the genes which encode proteins – revealed mutations in the INPP5K gene from each affected individual.

The research team went on to block the expression of this gene in zebrafish, which are commonly used model organisms for genetic studies. The affected fish showed similar symptoms to humans who carry the mutation, such as muscle damage and eye defects.

Muscular dystrophy is the term given to a group of progressive diseases that cause muscles to degenerate over time. The disease-causing mutation usually affects the functioning of genes that make proteins required to form and maintain muscles. However, this study revealed mutations in the INPP5K gene affect its function inside the cell, where it is involved with cell signalling and helps to process other proteins. This is why researchers have marked it as a new form of congenital MD.

While the authors note that this finding may not have an immediate impact on the children involved, the study could lead to faster and more precise diagnosis of the disease, and allow families to receive appropriate genetic counselling

'Early stage research identifying genes for muscle-wasting conditions, such as this, gives us valuable insight into better understanding these complex and rare conditions,' said Robert Meadowcroft, chief executive of Muscular Dystrophy UK.

He added that 'the results from this paper could help some families living with congenital MD to receive a faster diagnosis, paving the way for a potential treatment for this mutation in the future'.

The researchers involved in the study say that more work is needed to understand why the disruption identified in the gene leads to the disorder itself.

Gene for a New Form of Muscular Dystrophy Found by Researchers Funded by March of Dimes
PR Newswire |  9 February 2017
Genetic study identifies a new form of congenital muscular dystrophy
Science Daily |  9 February 2017
Mutations in INPP5K Cause a Form of Congenital Muscular Dystrophy Overlapping Marinesco-Sjögren Syndrome and Dystroglycanopathy
American Journal of Human Genetics |  9 February 2017
Researchers Identify New Congenital Muscular Dystrophy
Muscular Dystrophy News |  8 February 2017
17 May 2021 - by Dr Rosie Morley 
Accumulation of defective mitochondria in cells may contribute to autoimmune conditions, such as Sjögren's syndrome, according to a recent study...
31 July 2017 - by Jenny Sharpe 
A safe and effective gene therapy treating Duchenne muscular dystrophy in dogs has been demonstrated...
11 January 2016 - by Jenny Sharpe 
Scientists in the USA have shown that the genome-editing technique CRISPR can improve muscle function in a mouse model of Duchenne muscular dystrophy...
16 November 2015 - by Jenny Sharpe 
Researchers have discovered a gene linked to Duchenne muscular dystrophy (DMD) after a dog bred to model the disease was found to have a protective mutation against it...
23 September 2013 - by Dr Anna Cauldwell 
A highly anticipated experimental treatment for the genetic condition Duchenne Muscular Dystrophy has failed in a key test of its effectiveness in a critical phase III clinical trial.
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.